• United States
  • Biotechs

U.S. Biotechs Stocks Analysis

NasdaqGM:NRIX
NasdaqGM:NRIX
NasdaqGM:NRIX

Here's Why We're Not At All Concerned With Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

April 15, 2021Biotechs
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
NasdaqGM:EGRX
NasdaqGM:EGRX
NasdaqGM:EGRX

Eagle Pharmaceuticals (NASDAQ:EGRX) Could Easily Take On More Debt

April 15, 2021Biotechs
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
NasdaqGS:AMGN
NasdaqGS:AMGN
NasdaqGS:AMGN

Is Amgen Inc.'s (NASDAQ:AMGN) 77% ROE Better Than Average?

April 15, 2021Biotechs
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
NasdaqGS:ADAP
NasdaqGS:ADAP
NasdaqGS:ADAP

We Think Adaptimmune Therapeutics (NASDAQ:ADAP) Can Easily Afford To Drive Business Growth

April 15, 2021Biotechs
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
NasdaqCM:ELDN
NasdaqCM:ELDN
NasdaqCM:ELDN

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

April 14, 2021Biotechs
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
NasdaqGS:BIIB
NasdaqGS:BIIB
NasdaqGS:BIIB

Biogen Inc. (NASDAQ:BIIB) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

April 14, 2021Biotechs
It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined 2.1...
NasdaqCM:YTEN
NasdaqCM:YTEN
NasdaqCM:YTEN

Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Situation

April 14, 2021Biotechs
We can readily understand why investors are attracted to unprofitable companies. For example, Yield10 Bioscience...
NasdaqGM:XOMA
NasdaqGM:XOMA
NasdaqGM:XOMA

Declining Stock and Solid Fundamentals: Is The Market Wrong About XOMA Corporation (NASDAQ:XOMA)?

April 14, 2021Biotechs
With its stock down 8.3% over the past month, it is easy to disregard XOMA (NASDAQ:XOMA). But if you pay close...
NasdaqGM:XENE
NasdaqGM:XENE
NasdaqGM:XENE

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

April 14, 2021Biotechs
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
  • 1
  • 2
  • 3
  • 4
  • 5
Next

Become a better investor

Simply Wall St is an award winning start-up aiming to replace human stockbrokers by providing you with high quality financial data and analysis presented in a beautiful visual way everybody can understand, at a fraction of the cost (try our FREE plan).

Find out more
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
  • About
  • Company
  • Careers
  • Plans
  • Log In
  • Help Centre
  • Simply Wall St News
  • Podcasts
  • Financial Services Guide
  • Terms and Conditions
  • Privacy Policy

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.